These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

3511 related items for PubMed ID: 29054536

  • 1. Decreasing body mass index is associated with cerebrospinal fluid markers of Alzheimer's pathology in MCI and mild dementia.
    Mathys J, Gholamrezaee M, Henry H, von Gunten A, Popp J.
    Exp Gerontol; 2017 Dec 15; 100():45-53. PubMed ID: 29054536
    [Abstract] [Full Text] [Related]

  • 2. Progression to dementia in memory clinic patients with mild cognitive impairment and normal β-amyloid.
    Rosenberg A, Solomon A, Jelic V, Hagman G, Bogdanovic N, Kivipelto M.
    Alzheimers Res Ther; 2019 Dec 05; 11(1):99. PubMed ID: 31805990
    [Abstract] [Full Text] [Related]

  • 3. Markers of neuroinflammation associated with Alzheimer's disease pathology in older adults.
    Popp J, Oikonomidi A, Tautvydaitė D, Dayon L, Bacher M, Migliavacca E, Henry H, Kirkland R, Severin I, Wojcik J, Bowman GL.
    Brain Behav Immun; 2017 May 05; 62():203-211. PubMed ID: 28161476
    [Abstract] [Full Text] [Related]

  • 4. Incremental value of biomarker combinations to predict progression of mild cognitive impairment to Alzheimer's dementia.
    Frölich L, Peters O, Lewczuk P, Gruber O, Teipel SJ, Gertz HJ, Jahn H, Jessen F, Kurz A, Luckhaus C, Hüll M, Pantel J, Reischies FM, Schröder J, Wagner M, Rienhoff O, Wolf S, Bauer C, Schuchhardt J, Heuser I, Rüther E, Henn F, Maier W, Wiltfang J, Kornhuber J.
    Alzheimers Res Ther; 2017 Oct 10; 9(1):84. PubMed ID: 29017593
    [Abstract] [Full Text] [Related]

  • 5. Combining Cerebrospinal Fluid Biomarkers and Neuropsychological Assessment: A Simple and Cost-Effective Algorithm to Predict the Progression from Mild Cognitive Impairment to Alzheimer's Disease Dementia.
    Mazzeo S, Santangelo R, Bernasconi MP, Cecchetti G, Fiorino A, Pinto P, Passerini G, Falautano M, Comi G, Magnani G.
    J Alzheimers Dis; 2016 Oct 18; 54(4):1495-1508. PubMed ID: 27589522
    [Abstract] [Full Text] [Related]

  • 6. Varying strength of cognitive markers and biomarkers to predict conversion and cognitive decline in an early-stage-enriched mild cognitive impairment sample.
    Egli SC, Hirni DI, Taylor KI, Berres M, Regeniter A, Gass A, Monsch AU, Sollberger M.
    J Alzheimers Dis; 2015 Oct 18; 44(2):625-33. PubMed ID: 25322924
    [Abstract] [Full Text] [Related]

  • 7. Association between Cerebrospinal Fluid Biomarkers for Alzheimer's Disease, APOE Genotypes and Auditory Verbal Learning Task in Subjective Cognitive Decline, Mild Cognitive Impairment, and Alzheimer's Disease.
    Mandecka M, Budziszewska M, Barczak A, Pepłońska B, Chodakowska-Żebrowska M, Filipek-Gliszczyńska A, Nesteruk M, Styczyńska M, Barcikowska M, Gabryelewicz T.
    J Alzheimers Dis; 2016 Jul 29; 54(1):157-68. PubMed ID: 27472875
    [Abstract] [Full Text] [Related]

  • 8. Apolipoprotein E genotype and the diagnostic accuracy of cerebrospinal fluid biomarkers for Alzheimer disease.
    Lautner R, Palmqvist S, Mattsson N, Andreasson U, Wallin A, Pålsson E, Jakobsson J, Herukka SK, Owenius R, Olsson B, Hampel H, Rujescu D, Ewers M, Landén M, Minthon L, Blennow K, Zetterberg H, Hansson O, Alzheimer’s Disease Neuroimaging Initiative.
    JAMA Psychiatry; 2014 Oct 29; 71(10):1183-91. PubMed ID: 25162367
    [Abstract] [Full Text] [Related]

  • 9. Cognitive Variability Predicts Incident Alzheimer's Disease and Mild Cognitive Impairment Comparable to a Cerebrospinal Fluid Biomarker.
    Gleason CE, Norton D, Anderson ED, Wahoske M, Washington DT, Umucu E, Koscik RL, Dowling NM, Johnson SC, Carlsson CM, Asthana S, Alzheimer’s Disease Neuroimaging Initiative.
    J Alzheimers Dis; 2018 Oct 29; 61(1):79-89. PubMed ID: 29125485
    [Abstract] [Full Text] [Related]

  • 10. Amyloid cascade and tau pathology cerebrospinal fluid markers in mild cognitive impairment with regards to Alzheimer's disease cerebral metabolic signature.
    Alexopoulos P, Guo LH, Jiang M, Bujo H, Grimmer T, Förster S, Drzezga A, Kurz A, Perneczky R.
    J Alzheimers Dis; 2013 Oct 29; 36(2):401-8. PubMed ID: 23609762
    [Abstract] [Full Text] [Related]

  • 11. FDG-PET and CSF biomarker accuracy in prediction of conversion to different dementias in a large multicentre MCI cohort.
    Caminiti SP, Ballarini T, Sala A, Cerami C, Presotto L, Santangelo R, Fallanca F, Vanoli EG, Gianolli L, Iannaccone S, Magnani G, Perani D, BIOMARKAPD Project.
    Neuroimage Clin; 2018 Oct 29; 18():167-177. PubMed ID: 29387532
    [Abstract] [Full Text] [Related]

  • 12. Alzheimer's Disease Assessment Scale-Cognitive subscale variants in mild cognitive impairment and mild Alzheimer's disease: change over time and the effect of enrichment strategies.
    Podhorna J, Krahnke T, Shear M, Harrison JE, Alzheimer’s Disease Neuroimaging Initiative.
    Alzheimers Res Ther; 2016 Feb 12; 8():8. PubMed ID: 26868820
    [Abstract] [Full Text] [Related]

  • 13. Cerebrospinal fluid cortisol and clinical disease progression in MCI and dementia of Alzheimer's type.
    Popp J, Wolfsgruber S, Heuser I, Peters O, Hüll M, Schröder J, Möller HJ, Lewczuk P, Schneider A, Jahn H, Luckhaus C, Perneczky R, Frölich L, Wagner M, Maier W, Wiltfang J, Kornhuber J, Jessen F.
    Neurobiol Aging; 2015 Feb 12; 36(2):601-7. PubMed ID: 25435336
    [Abstract] [Full Text] [Related]

  • 14. Association of Cerebrospinal Fluid S100B Protein with Core Biomarkers and Cognitive Deficits in Prodromal and Mild Alzheimer's Disease.
    Christl J, Verhülsdonk S, Pessanha F, Menge T, Seitz RJ, Kujovic M, Höft B, Supprian T, Lange-Asschenfeldt C.
    J Alzheimers Dis; 2019 Feb 12; 72(4):1119-1127. PubMed ID: 31683478
    [Abstract] [Full Text] [Related]

  • 15. Plasma Proteomic Profiles of Cerebrospinal Fluid-Defined Alzheimer's Disease Pathology in Older Adults.
    Dayon L, Wojcik J, Núñez Galindo A, Corthésy J, Cominetti O, Oikonomidi A, Henry H, Migliavacca E, Bowman GL, Popp J.
    J Alzheimers Dis; 2017 Feb 12; 60(4):1641-1652. PubMed ID: 29125490
    [Abstract] [Full Text] [Related]

  • 16. Evaluation of visinin-like protein 1 concentrations in the cerebrospinal fluid of patients with mild cognitive impairment as a dynamic biomarker of Alzheimer's disease.
    Mroczko B, Groblewska M, Zboch M, Muszyński P, Zajkowska A, Borawska R, Szmitkowski M, Kornhuber J, Lewczuk P.
    J Alzheimers Dis; 2015 Feb 12; 43(3):1031-7. PubMed ID: 25159667
    [Abstract] [Full Text] [Related]

  • 17. Cerebrospinal fluid levels of β-amyloid 1-42, but not of tau, are fully changed already 5 to 10 years before the onset of Alzheimer dementia.
    Buchhave P, Minthon L, Zetterberg H, Wallin AK, Blennow K, Hansson O.
    Arch Gen Psychiatry; 2012 Jan 12; 69(1):98-106. PubMed ID: 22213792
    [Abstract] [Full Text] [Related]

  • 18. Cognitive impairment in late-life bipolar disorder is not associated with Alzheimer's disease pathological signature in the cerebrospinal fluid.
    Forlenza OV, Aprahamian I, Radanovic M, Talib LL, Camargo MZ, Stella F, Machado-Vieira R, Gattaz WF.
    Bipolar Disord; 2016 Feb 12; 18(1):63-70. PubMed ID: 26876913
    [Abstract] [Full Text] [Related]

  • 19. T1rho MRI and CSF biomarkers in diagnosis of Alzheimer's disease.
    Haris M, Yadav SK, Rizwan A, Singh A, Cai K, Kaura D, Wang E, Davatzikos C, Trojanowski JQ, Melhem ER, Marincola FM, Borthakur A.
    Neuroimage Clin; 2015 Feb 12; 7():598-604. PubMed ID: 25844314
    [Abstract] [Full Text] [Related]

  • 20. Cerebrospinal fluid synaptosomal-associated protein 25 is a key player in synaptic degeneration in mild cognitive impairment and Alzheimer's disease.
    Zhang H, Therriault J, Kang MS, Ng KP, Pascoal TA, Rosa-Neto P, Gauthier S, Alzheimer’s Disease Neuroimaging Initiative.
    Alzheimers Res Ther; 2018 Aug 16; 10(1):80. PubMed ID: 30115118
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 176.